DK2621282T3 - Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes - Google Patents

Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes Download PDF

Info

Publication number
DK2621282T3
DK2621282T3 DK11833060.4T DK11833060T DK2621282T3 DK 2621282 T3 DK2621282 T3 DK 2621282T3 DK 11833060 T DK11833060 T DK 11833060T DK 2621282 T3 DK2621282 T3 DK 2621282T3
Authority
DK
Denmark
Prior art keywords
treatment
gaba
prophylaxy
diabetes
combinations
Prior art date
Application number
DK11833060.4T
Other languages
English (en)
Inventor
Daniel Kaufman
Jide Tian
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK2621282T3 publication Critical patent/DK2621282T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK11833060.4T 2010-09-28 2011-09-28 Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes DK2621282T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38739810P 2010-09-28 2010-09-28
US201161433089P 2011-01-14 2011-01-14
PCT/US2011/053732 WO2012050907A2 (en) 2010-09-28 2011-09-28 Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes

Publications (1)

Publication Number Publication Date
DK2621282T3 true DK2621282T3 (da) 2020-05-04

Family

ID=45938872

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11833060.4T DK2621282T3 (da) 2010-09-28 2011-09-28 Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes

Country Status (5)

Country Link
US (5) US9089531B2 (da)
EP (2) EP3753410A3 (da)
CN (2) CN107050456B (da)
DK (1) DK2621282T3 (da)
WO (1) WO2012050907A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2571503E (pt) 2010-05-14 2015-04-29 Dana Farber Cancer Inst Inc Composições e a sua utilização no tratamento de neoplasia, doença inflamatória e outros distúrbios
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
ES2666465T3 (es) 2012-09-27 2018-05-04 Institut National De La Santé Et De La Recherche Médicale (Inserm) Métodos para producir una población de células beta pancreáticas
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
KR101740583B1 (ko) 2014-02-17 2017-05-29 경희대학교 산학협력단 비만 억제 효능을 갖는 신규 유산균 및 이의 용도
MX2016011160A (es) * 2014-02-28 2017-04-27 Tensha Therapeutics Inc Tratamiento de afecciones asociadas con la hiperinsulinemia.
RS60581B1 (sr) * 2014-06-04 2020-08-31 Diamyd Medical Ab Dekarboksilaza glutamske kiseline (gad) za upotrebu u lečenju autoimune bolesti
US10980866B2 (en) 2014-09-22 2021-04-20 Hadasit Medical Research Services And Development Ltd. Alpha-1 anti-trypsin for treating liver diseases
EP3212654B1 (en) 2014-10-27 2020-04-08 Tensha Therapeutics, Inc. Bromodomain inhibitors
BR112018000933A2 (pt) 2015-07-17 2018-09-04 Ovid Therapeutics Inc métodos de tratamento de um distúrbio de desenvolvimento
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
CA2996293C (en) 2015-08-21 2023-12-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and systems for measuring growth rate in plant or aquatic animal species
US11053295B2 (en) * 2015-08-21 2021-07-06 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Peptides having effects of preventing or treating central nervous system diseases and pharmaceutical compositions for preventing or treating central nervous system diseases containing same as active ingredient
KR20180054796A (ko) * 2015-10-14 2018-05-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 베타 세포 복제 및/또는 생존의 향상
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CA3018960C (en) 2016-03-28 2023-09-26 The Regents Of The University Of California Method and composition for treating neuronal hyper-excitability
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
GB201707207D0 (en) * 2017-05-05 2017-06-21 Galvani Bioelectronics Ltd Treatment of type 1 diabetes
CA3065113A1 (en) * 2017-05-26 2018-11-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for regulating glucose homeostasis
EP3642206A4 (en) * 2017-06-23 2021-04-07 The Regents of The University of California IMPROVING THE CAPACITY OF GABA TO MODULATE IMMUNE RESPONSES
KR20200047557A (ko) * 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
US11707535B2 (en) 2017-09-08 2023-07-25 The Regents Of The University Of California Method and composition for treating neuropathic pain
KR101938991B1 (ko) * 2017-09-25 2019-01-15 강원대학교산학협력단 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물
US11020405B2 (en) 2017-09-25 2021-06-01 Kangwon National University University-Industry Cooperation Foundation Method for prevention or treatment of diabetic complications
EP3755314A1 (en) * 2018-02-22 2020-12-30 Diamyd Medical AB Gaba a receptor agonists for treatment of disorders influenced by dysfunction beta cells
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
CN113286596A (zh) * 2018-10-12 2021-08-20 西奈山伊坎医学院 AZD3355(Lesogaberan)用于治疗和预防非酒精性脂肪性肝炎(NASH)、肝纤维化及其他肝脏病症
WO2020081886A1 (en) * 2018-10-18 2020-04-23 The Regents Of The University Of California Homotaurine for treatment of inflammation-related disorders
EP3880201A4 (en) 2018-12-17 2022-07-27 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF NON-24 HOUR SLEEP waking disorder
US10980566B2 (en) 2019-01-10 2021-04-20 The Regents Of The University Of California Subpial delivery system and methods of use
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3148083A1 (en) * 2019-08-09 2021-02-18 Diamyd Medical Ab Preventing and treating hypoglycemia
CN111035755B (zh) * 2020-01-08 2023-04-14 中国医学科学院医学生物学研究所 一种1型糖尿病疫苗及其制备方法
USD963164S1 (en) 2020-01-09 2022-09-06 The Regents Of The University Of California Surgical needle
BR112022025381A2 (pt) 2020-06-11 2023-01-24 Provention Bio Inc Métodos e composições para prevenir diabetes tipo 1
CN116115758A (zh) * 2022-11-22 2023-05-16 上海市内分泌代谢病研究所 Gabaa受体作为靶点在制备或筛选降血脂、治疗肥胖和/或改善代谢的药物中的应用
US20240285565A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US504826A (en) 1893-09-12 Territory
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
GB8820266D0 (en) 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
FR2663934B1 (fr) 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CN1112943C (zh) 1994-01-21 2003-07-02 粉剂注射疫苗股份有限公司 气体驱动的基因送递装置
US5637617A (en) 1994-04-01 1997-06-10 The Regents Of The University Of California Methods for use of GABAa receptor GABAergic compounds
HUP9901138A3 (en) 1995-06-06 1999-11-29 Cocensys Inc Irvine Neuroactive steroids of the androstane and pregnane series
US5723462A (en) 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
AU724076B2 (en) 1996-07-25 2000-09-14 Merck Sharp & Dohme Limited Substituted triazolo pyridazine derivatives as inverse agonists of the GABAAalpha5 receptor subtype
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
US6022697A (en) * 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
AU1041599A (en) 1997-11-13 1999-06-07 Jose Luis Castro Pineiro Therapeutic uses of triazolo-pyridazine derivatives
GB9801210D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GEP20032868B (en) 1998-01-21 2003-01-27 Merck Sharp & Dohme Triazolo-Pyridazine Derivatives as Ligands for Gaba Receptors, Methods for Their Production, Pharmaceutical Compositions Containing the Same for Treatment and/or Prevention of disorders of Central Nervous System
GB9801234D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
ATE296290T1 (de) 1998-02-26 2005-06-15 Neurogen Corp Substituierte cycloalkyl-4-oxonicotinische karboxamide; gaba gehirn-rezeptorligande
GB9806102D0 (en) 1998-03-20 1998-05-20 Merck Sharp & Dohme Therapeutic agents
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
US20080255093A1 (en) 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
US7319095B2 (en) 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
AU2001275186A1 (en) * 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
EP1343805A4 (en) 2000-10-06 2005-07-20 Xenoport Inc COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2002042414A2 (en) 2000-11-17 2002-05-30 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
DE60106968T2 (de) * 2000-11-30 2005-11-03 Pfizer Products Inc., Groton Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
KR100729645B1 (ko) * 2000-12-29 2007-06-18 주식회사 녹십자홀딩스 글루타민산 데카르복실라제를 코딩하는 유전자가 삽입된재조합 백시니아 바이러스 및 이를 포함하는 제 1형당뇨병 예방 백신
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US20030162754A1 (en) * 2001-12-17 2003-08-28 Tufts University Use of GABA and GABAB agonists
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
JP5180092B2 (ja) * 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
EP2058008B1 (en) * 2006-08-11 2013-08-21 National University Corporation Nagoya University Anti-obesity agent and use thereof
JP2009298742A (ja) 2008-06-16 2009-12-24 Toyobo Co Ltd 生活習慣病改善剤
US8680051B2 (en) * 2008-12-19 2014-03-25 Qinghua Wang Method of ameliorating symptoms of type 1-diabetes using GABA related compounds and GLP-1/exendin-4 compounds
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合

Also Published As

Publication number Publication date
EP3753410A2 (en) 2020-12-23
US9820955B2 (en) 2017-11-21
CN103228142A (zh) 2013-07-31
US10952980B2 (en) 2021-03-23
WO2012050907A2 (en) 2012-04-19
US20210205248A1 (en) 2021-07-08
EP2621282A2 (en) 2013-08-07
CN107050456B (zh) 2022-08-12
EP3753410A3 (en) 2021-04-28
US10434078B2 (en) 2019-10-08
US9089531B2 (en) 2015-07-28
CN107050456A (zh) 2017-08-18
EP2621282A4 (en) 2014-05-07
EP2621282B1 (en) 2020-04-15
US11872200B2 (en) 2024-01-16
US20200030272A1 (en) 2020-01-30
US20180193295A1 (en) 2018-07-12
WO2012050907A3 (en) 2012-06-21
US20160081956A1 (en) 2016-03-24
US20130251671A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
DK2621282T3 (da) Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
DK2555807T5 (da) Skabelon-øceller og små øcelleklynger til behandling af diabetes
DK2744456T3 (da) Forbedringer ved eller i forbindelse med proteser og ortoser
DK3421486T5 (da) Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
DK2575830T4 (da) Forud fortykket, kompakt og flydende næringssammensætning til patienter med dysfagi
DK2470517T3 (da) Estere af 2,5-furandicarboxylsyre med isomere decanoler og anvendelse heraf
DK2448637T4 (da) Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi
SG2014013874A (en) Polyamic acid resin composition, polyimide resin composition, polyimide oxazole resin composition, and flexible substrate containing same
DK2643029T3 (da) Præparat og/eller formulering af proteiner, som er tværbundet med polysaccharider
DK2787861T3 (da) Forbedringer i og i forbindelse med puder
DK2505150T3 (da) Okklusionsindretning med porøs struktur og stræk-resistent element
EE201300007A (et) Kombineeritud ravimkoostis diabeedi ning ainevahetush„irete raviks
DK3459558T3 (da) Glycoproteiner med lipidmobiliserende egenskaber og terapeutiske anvendelser deraf
DK2603226T3 (da) Behandling af diabetes med endokrine pankreas-prækursorceller
DK2531181T3 (da) Formuleringer af rasagilin med forlænget afgivelse og anvendelser deraf
DK2967040T3 (da) Biocidholdig sammensætning og fremgangsmåde til behandling af vand eller overflader i kontakt med vand
DK2120923T3 (da) Anvendelse af substituerede pyranonsyrederivater til behandling af det metaboliske syndrom
DK3098224T3 (da) Pyranochromenyl-phenolderivat og farmaceutisk sammensætning til behandling af metabolisk syndrom eller inflammationssygdom
DK2702992T3 (da) Anvendelse af melatonin til behandling af og/eller forebyggelse af mucositis
DK2576782T3 (da) Sirna og anvendelse deraf i fremgangsmåder og sammensætninger til behandling og/eller forebyggelse af øjentilstande
DK2459218T3 (da) Opløsninger med polyethylengycol og elektrolytter
DK2895856T3 (da) Diagnose og behandling af mobilitetsforstyrrelser i tarm og blære, og af fibromyalgi
FI20106220A (fi) Menetelmä ja järjestely rullainkäytön yhteydessä
DK3363437T3 (da) Aminoindanforbindelser og anvendelse deraf i behandling af smerte
DK2646039T3 (da) Sammensætning og anvendelse deraf i behandlingen af analrhagader